Characterising the autoantibody repertoire in systemic sclerosis following myeloablative haematopoietic stem cell transplantation
Abstract
Results from the SCOT (Scleroderma: Cyclophosphamide Or Transplantation) clinical trial demonstrated significant benefits of haematopoietic stem cell transplant (HSCT) versus cyclophosphamide (CTX) in patients with systemic sclerosis. The objective of this study was to test the hypothesis that transplantation stabilises the autoantibody repertoire in patients with favourable clinical outcomes.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 18, 2023
- Source ID
- 10.1136/ard-2021-221926
Entities
People
- Ashley Pinckney
- Beverly Welch
- Burcu Ayoglu
- Daniel E. Furst
- Ellen Goldmuntz
- Judith A James
- Keith M. Sullivan
- Leslie J. Crofford
- Lorinda Chung
- Lynette Keyes-elstein
- Maureen D Mayes
- Michele Donato
- Paul J. Utz
- Peter Mcsweeney
- Purvesh Khatri
- Richard A. Nash
- Rong Mao
- Susan Macwana
Organizations
- Donald E. and Delia B. Baxter Foundation
- Knut and Alice Wallenberg Foundation
- National Institute of Allergy and Infectious Diseases
- National Institutes of Health
- Scleroderma Research Foundation
- United States Department of Defense